26.68 USD
▲+1.90+7.67%
盘后 26.95 +1.01%
2026-09-15
市值
$4.42B
市盈率
—
EPS
-0.41
股息率
—
52 周区间
12.00 – 27.34
成交量
4.12M
Beta
2.10
目标价
25.07
52W 低 12.0052W 高 27.34
价格走势
公司简介
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima...
关联新闻
- Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode